172 related articles for article (PubMed ID: 36544031)
1. Exploring binding mode assessment of novel kaempferol, resveratrol, and quercetin derivatives with PPAR-α as potent drug candidates against cancer.
Ballav S; Lokhande KB; Yadav RS; Ghosh P; Swamy KV; Basu S
Mol Divers; 2023 Dec; 27(6):2867-2885. PubMed ID: 36544031
[TBL] [Abstract][Full Text] [Related]
2. Probing intermolecular interactions and binding stability of kaempferol, quercetin and resveratrol derivatives with PPAR-γ: docking, molecular dynamics and MM/GBSA approach to reveal potent PPAR- γ agonist against cancer.
Lokhande KB; Ballav S; Yadav RS; Swamy KV; Basu S
J Biomol Struct Dyn; 2022 Feb; 40(3):971-981. PubMed ID: 32954977
[TBL] [Abstract][Full Text] [Related]
3. Exploring conformational changes of PPAR-Ɣ complexed with novel kaempferol, quercetin, and resveratrol derivatives to understand binding mode assessment: a small-molecule checkmate to cancer therapy.
Lokhande KB; Ballav S; Thosar N; Swamy KV; Basu S
J Mol Model; 2020 Aug; 26(9):242. PubMed ID: 32816149
[TBL] [Abstract][Full Text] [Related]
4. In silico and in vitro analysis of PPAR - α / γ dual agonists: Comparative evaluation of potential phytochemicals with anti-obesity drug orlistat.
Mandal SK; Kumar BK; Sharma PK; Murugesan S; Deepa PR
Comput Biol Med; 2022 Aug; 147():105796. PubMed ID: 35809408
[TBL] [Abstract][Full Text] [Related]
5. Computational investigation of phytochemicals from
Omoboyowa DA; Singh G; Fatoki JO; Oyeneyin OE
J Biomol Struct Dyn; 2023; 41(12):5568-5582. PubMed ID: 35773777
[TBL] [Abstract][Full Text] [Related]
6. Discovery of New Dual-Target Agents Against PPAR-γ and α-Glucosidase Enzymes with Molecular Modeling Methods: Molecular Docking, Molecular Dynamic Simulations, and MM/PBSA Analysis.
Kaya S; Tatar-Yılmaz G; Aktar BSK; Emre EEO
Protein J; 2024 Jun; 43(3):577-591. PubMed ID: 38642318
[TBL] [Abstract][Full Text] [Related]
7. Flavonostilbenes natural hybrids from
Elsaman T; Ahmad I; Eltayib EM; Suliman Mohamed M; Yusuf O; Saeed M; Patel H; Mohamed MA
J Biomol Struct Dyn; 2024 Apr; 42(6):3249-3266. PubMed ID: 37261483
[TBL] [Abstract][Full Text] [Related]
8. The effect of quercetin and kaempferol aglycones and glucuronides on peroxisome proliferator-activated receptor-gamma (PPAR-γ).
Beekmann K; Rubió L; de Haan LH; Actis-Goretta L; van der Burg B; van Bladeren PJ; Rietjens IM
Food Funct; 2015 Apr; 6(4):1098-107. PubMed ID: 25765892
[TBL] [Abstract][Full Text] [Related]
9. Biological evaluation and structural insights for design of subtype-selective peroxisome proliferator activated receptor-α (PPAR-α) agonists.
Gangwal RP; Damre MV; Das NR; Sharma SS; Sangamwar AT
Bioorg Med Chem Lett; 2015 Jan; 25(2):270-5. PubMed ID: 25491112
[TBL] [Abstract][Full Text] [Related]
10. Identification of phytochemicals as putative ligands for the targeted modulation of peroxisome proliferator-activated receptor α (PPARα) in animals.
Hassan FU; Rehman MS; Javed M; Ahmad K; Fatima I; Safdar M; Ashraf N; Nadeem A
J Biomol Struct Dyn; 2023 Oct; ():1-12. PubMed ID: 37837423
[TBL] [Abstract][Full Text] [Related]
11. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
[TBL] [Abstract][Full Text] [Related]
12. Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.
Ma Y; Wang SQ; Xu WR; Wang RL; Chou KC
PLoS One; 2012; 7(6):e38546. PubMed ID: 22685582
[TBL] [Abstract][Full Text] [Related]
13. Phenolic compounds as potential adenosine deaminase inhibitors: molecular docking and dynamics simulation coupled with MM-GBSA calculations.
Uba AI; Paradis NJ; Wu C; Zengin G
Amino Acids; 2023 Dec; 55(12):1729-1743. PubMed ID: 37517044
[TBL] [Abstract][Full Text] [Related]
14. Structure based docking and molecular dynamics studies: Peroxisome proliferator-activated receptors -α/γ dual agonists for treatment of metabolic disorders.
Nath V; Agrawal R; Kumar V
J Biomol Struct Dyn; 2020 Feb; 38(2):511-523. PubMed ID: 30767625
[TBL] [Abstract][Full Text] [Related]
15. Novel Phenoxazinones as potent agonist of PPAR-α: design, synthesis, molecular docking and in vivo studies.
Ugwu DI; Okoro UC; Mishra NK; Okafor SN
Lipids Health Dis; 2018 May; 17(1):120. PubMed ID: 29789011
[TBL] [Abstract][Full Text] [Related]
16. In silico Discovery of Resveratrol Analogues as Potential Agents in Treatment of Metabolic Disorders.
Pavlović N; Đanić M; Stanimirov B; Goločorbin-Kon S; Stankov K; Lalić-Popović M; Mikov M
Curr Pharm Des; 2019; 25(35):3776-3783. PubMed ID: 31663474
[TBL] [Abstract][Full Text] [Related]
17. In silico discovery of 3 novel quercetin derivatives against papain-like protease, spike protein, and 3C-like protease of SARS-CoV-2.
Bhattacharya K; Bordoloi R; Chanu NR; Kalita R; Sahariah BJ; Bhattacharjee A
J Genet Eng Biotechnol; 2022 Mar; 20(1):43. PubMed ID: 35262828
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening, pharmacokinetics & MD simulation study of active phytoconstituents of
Deshpande N S; Dwivedi PSR; Revanasiddappa BC
J Biomol Struct Dyn; 2023 Nov; ():1-17. PubMed ID: 37948295
[No Abstract] [Full Text] [Related]
19. Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine.
Chen KC; Chang SS; Huang HJ; Lin TL; Wu YJ; Chen CY
J Biomol Struct Dyn; 2012; 30(6):662-83. PubMed ID: 22731403
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
